Pharmacological research · 2025
Protective effect and mechanisms of puerarin in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis of animal studies.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zou Xiang-Yun, Yang Yu-Cheng, Liu Xue-Han, Qi Wen-Ying, Zao Xiao-Bin, Li Xiao-Ke, Ye Yong'an
Аннотация
BACKGROUND AND AIMS: Puerarin is a plant-derived isoflavone compound. It has been shown to exert beneficial effects on a variety of diseases. Previous studies suggested that puerarin may offer therapeutic benefits in the intervention of metabolic dysfunction-associated steatotic liver disease (MASLD). However, there is currently no evidence from evidence-based medicine. Therefore, we conducted a systematic review of preclinical studies investigating the effects of puerarin on MASLD and to explore the underlying mechanisms of action.
METHODS: We systematically searched eight Chinese and English databases from their inception to April 12, 2025. A total of 19 relevant studies, published in both Chinese and English, were included in the analysis. Data analysis was performed using R (version 4.5.0). The primary outcomes were total cholesterol (TC), triglycerides (TG), alanine aminotransferase (ALT), and aspartate aminotransferase (AST).
RESULTS: ]Puerarin significantly improved TC, TG, ALT, and AST levels. In addition, it also improved other lipid parameters, including low-density lipoprotein cholesterol and high-density lipoprotein cholesterol. It also reduced body weight, liver weight, and hepatic index in animal models. Furthermore, puerarin decreased inflammatory cytokines such as tumor necrosis factor-α, interleukin-1β, and interleukin-6. It also improved oxidative stress markers, including malondialdehyde, superoxide dismutase, and glutathione peroxidase.
CONCLUSIONS: Puerarin may improve MASLD by regulating lipid metabolism, reducing inflammation, and exerting antioxidant effects. These findings provide preclinical support for the potential therapeutic use of puerarin in the management of MASLD. However, its efficacy and safety require further confirmation through larger and higher-quality preclinical studies.
METHODS: We systematically searched eight Chinese and English databases from their inception to April 12, 2025. A total of 19 relevant studies, published in both Chinese and English, were included in the analysis. Data analysis was performed using R (version 4.5.0). The primary outcomes were total cholesterol (TC), triglycerides (TG), alanine aminotransferase (ALT), and aspartate aminotransferase (AST).
RESULTS: ]Puerarin significantly improved TC, TG, ALT, and AST levels. In addition, it also improved other lipid parameters, including low-density lipoprotein cholesterol and high-density lipoprotein cholesterol. It also reduced body weight, liver weight, and hepatic index in animal models. Furthermore, puerarin decreased inflammatory cytokines such as tumor necrosis factor-α, interleukin-1β, and interleukin-6. It also improved oxidative stress markers, including malondialdehyde, superoxide dismutase, and glutathione peroxidase.
CONCLUSIONS: Puerarin may improve MASLD by regulating lipid metabolism, reducing inflammation, and exerting antioxidant effects. These findings provide preclinical support for the potential therapeutic use of puerarin in the management of MASLD. However, its efficacy and safety require further confirmation through larger and higher-quality preclinical studies.